CA
NZ
UK
AU
IND
US
This notable outperformance reflects the company's recovery efforts, particularly in response to pressures from elevated medical costs within its government insurance plans. Such financial resilience is important as it signals not only operational recovery but also confidence in sustaining growth, making it increasingly attractive …
Elite Pharmaceuticals introduced a generic version of Requip XL in five dosages, targeting the $10 million market for the branded product. Investors gain a new revenue source that could diversify earnings and offset the stock’s 26.2% YTD decline, offering upside if the drug gains …
DataMeds AI, Inc. has entered into an Amended and Restated Letter of Intent to acquire or license certain Quality of Life Peace of Mind-related intellectual property assets, expanding its existing PharmacyChain license, and acquiring a controlling interest in Tollo Health, LLC. The proposed transaction …
DaVita Inc. (NYSE: DVA) delivered a diluted earnings per share of $4.02 for the quarter ending June 30, 2026, surpassing the consensus estimate of $3.92. This positive result reflects an effective operational strategy, strongly positioning DaVita amidst a competitive healthcare environment. The company’s revenue …
60 Degrees Pharmaceuticals, Inc. has executed a private placement that raises approximately $1.0 million through an issuance of 191,571 shares priced at $1.74 apiece. The transaction is designed to enhance the company’s working capital, particularly for its research and development initiatives. This substantial funding …
Dianthus Therapeutics (NASDAQ: DNTH) announced that its second‑quarter research and development outlay reached $48.7 million, a stark rise from $26.3 million reported a year earlier. The surge is tied to heightened clinical spending on its claseprubart program and expanding headcount. Investors watching the biotech …
Diversified Healthcare Trust (NASDAQ: DHC) posted stronger-than-expected second-quarter earnings with an EPS of $0.16, compared to a consensus estimate of a $-0.15 loss for the quarter ended June 30, 2026. This notable performance highlights the company’s ongoing operational improvements within its healthcare property portfolio. …
EHealth, Inc. (NASDAQ: EHTH) posted a second-quarter loss per share of $-1.10, significantly missing the $-0.72 consensus estimate. Revenue for Q2 2026 fell 45% year-over-year, totaling $33.6 million, primarily due to a decline in Medicare enrollment. This sharp downturn raises concerns among investors about …
Operating in a difficult market, eHealth, Inc. reported total revenue of $33.6 million for Q2 2026, a 45% decline from the previous year. This drop starkly contrasts with analyst expectations, as the earnings per share (EPS) registered at $-1.10, falling short of the consensus …
Revenue Rises 5.5% to $6.3B Amid Mixed Results
Please wait processing your request...